Compare Allbirds Inc (BIRD) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allbirds Inc vs Sanofi SA — how do they compare? Allbirds Inc trades at $2.6 (market cap $30.00M), while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 3476.7× Allbirds Inc's market cap, and Sanofi SA pays a 5.55% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.
| BIRD | SNY | |
|---|---|---|
Market Cap | $30.00M | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $16.99 | $52.34 |
52-Week Low | $2.21 | $41.33 |
Enterprise Value | $48.86M | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIRD trades at $2.58, up 1.98% today, amid a strategic pivot from footwear to AI infrastructure, rebranding as Smartbird. Despite negative profitability and cash burn, the stock shows bullish technical signals and surged on recent leadership changes. Revenue has declined from $298M in 2022 to $152M in 2025, with net losses persisting but improving from -$152M to -$77M over the period.
Outlook hinges on successful AI transition, but high execution risk and sustained losses warrant caution. Analysts are mostly neutral, with 79% hold ratings. The stock offers speculative upside if new strategy gains traction, yet faces significant financial and competitive headwinds.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
